IL2 and acute myeloid leukemia: Miller and colleagues showed that there is a correlation between in vivo NK cell persistence and expansion of ≥ 100 donor NK cells/μl blood at day 7–14 after infusion in combination with in vivo IL2 boosting and achievement of CR in relapsed/refractory AML patients [5].